The FDA has approved AstraZeneca and Merck's Lynparza as a first-line maintenance therapy for patients who have BRCA mutations and advanced pancreatic cancer that has spread beyond the pancreas but not worsened after 16 weeks of chemotherapy. The drug was previously approved as treatment for breast and ovarian cancers.
FDA approves use of Lynparza for advanced pancreatic cancer
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.